Moderators and mediators of symptoms and quality of life outcomes in an open-label study of adults treated for attention-deficit/hyperactivity disorder

Journal of Clinical Psychiatry

Volumn 71, Issue 4, 2010, Pages 381-390

  Weiss, Margaret D ^a   Gibbins, Christopher ^a   Goodman, David W ^b,c   Hodgkins, Paul S ^d   Landgraf, Jeanne M ^e   Faraone, Stephen V ^f  

^a CHILDREN S AND WOMEN S HEALTH CENTRE OF BRITISH COLUMBIA   (Canada)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Adult Attention Deficit Disorder Center of Maryland   (United States)

^d SHIRE   (United States)

^e HealthActCHQ Inc   (United States)

^f STATE UNIVERSITY OF NEW YORK   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; AMPHETAMINE DERIVATIVE; ATOMOXETINE;

ADULT; ADULT DISEASE; ARTICLE; ATTENTION DEFICIT DISORDER; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PATIENT SATISFACTION; PRIORITY JOURNAL; QUALITY OF LIFE; REMISSION; SYMPTOM; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGE FACTORS; AMPHETAMINES; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; COMMUNITY MENTAL HEALTH SERVICES; DELAYED-ACTION PREPARATIONS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEALTH STATUS; HUMANS; MALE; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT SATISFACTION; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; SEX FACTORS; TREATMENT OUTCOME;

EID: 77951081496     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.08m04709pur     Document Type: Article

References (44)

1. Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006;163(4):716-723. (Pubitemid 44464584)
2. Faraone SV, Biederman J. What is the prevalence of adult ADHD? results of a population screen of 966 adults. J Atten Disord. 2005;9(2):384-391. (Pubitemid 41608110)
3. Able SL, Johnston JA, Adler LA, et al. Functional and psychosocial impairment in adults with undiagnosed ADHD. Psychol Med. 2007;37(1):97-107. (Pubitemid 46043846)
4. Adler LA, Spencer TJ, Levine LR, et al. Functional outcomes in the treatment of adults with ADHD. J Atten Disord. 2007;11(6):720-727.
5. Goodman DW. The consequences of attention-deficit/hyperactivity disorder in adults. J Psychiatr Pract. 2007;13(5):318-327.
6. Seidman LJ, Biederman J, Valera EM, et al. Neuropsychological functioning in girls with attention-deficit/hyperactivity disorder with and without learning disabilities. Neuropsychology. 2006;20(2):166-177.
7. Faraone SV, Wilens TE, Petty C, et al. Substance use among ADHD adults: implications of late onset and subthreshold diagnoses. Am J Addict. 2007;16(suppl 1):24-32. (Pubitemid 46633917)
8. Davidson MA. Literature review: ADHD in adults: a review of the literature. J Atten Disord. 2008;11(6):628-641.
9. Spencer TJ. Pharmacology of adult ADHD with stimulants. CNS Spectr. 2007;12(4, suppl 6):8-11.
10. Weiss MD, Safren SA, Solanto M, et al. Research forum on psychological treatment of adults with ADHD. J Atten Disord. 2008;11(6):642-651.
11. Steele M, Weiss M, Swanson J, et al. A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder. Can J Clin Pharmacol. 2006;13(1):e50-e62. (Pubitemid 46165597)
12. Landgraf JM, Rich M, Rappaport L. Measuring quality of life in children with attention-deficit/hyperactivity disorder and their families: development and evaluation of a new tool. Arch Pediatr Adolesc Med. 2002;156(4):384-391. (Pubitemid 34274187)
13. Ambrosini PJ, Sallee FR, Lopez FA, et al. A community assessment, open-label study of the safety, tolerability, and effectiveness of mixed amphetamine salts extended release in school-age children with ADHD. Curr Med Res Opin. 2006;22(2):427-440.
14. Ralston SJ, Lorenzo MJ. ADORE-Attention-Deficit Hyperactivity Disorder Observational Research in Europe. Eur Child Adolesc Psychiatry. 2004;13(suppl 1):I36-I42.
15. Molina BS, Hinshaw SP, Swanson JM, et al. The MTA at 8 years: prospective follow-up of children treated for combined-type ADHD in a multisite study. J Am Acad Child Adolesc Psychiatry. 2009;48(5):484-500.
16. Klassen AF, Miller A, Fine S. Health-related quality of life in children and adolescents who have a diagnosis of attention-deficit/hyperactivity disorder. Pediatrics. 2004;114(5):e541-e547. (Pubitemid 41655750)
17. Gordon M, Antshel K, Faraone S, et al. Symptoms versus impairment: the case for respecting DSM-IV's Criterion D. J Atten Disord. 2006;9(3):465-475. (Pubitemid 43171140)
18. Adler LA, Sutton VK, Moore RJ, et al. Quality of life assessment in adult patients with attention-deficit/hyperactivity disorder treated with atomoxetine. J Clin Psychopharmacol. 2006;26(6):648-652. (Pubitemid 44772744)
19. Matza LS, Johnston JA, Faries DE, et al. Responsiveness of the Adult Attention-Deficit/Hyperactivity Disorder Quality of Life Scale (AAQoL). Qual Life Res. 2007;16(9):1511-1520. (Pubitemid 47561727)
20. Goodman DW, Ginsberg L, Weisler RH, et al. An interim analysis of the Quality of Life, Effectiveness, Safety, and Tolerability (QU.E.S.T.) evaluation of mixed amphetamine salts extended release in adults with ADHD. CNS Spectr. 2005;10(12, suppl 20):26-34. (Pubitemid 43010495)
21. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR). Washington, DC: American Psychiatric Association; 2000.
22. Jain U, Hechtman L, Quinn D, et al. Canadian Attention Deficit Hyperactivity Disorder Resource Alliance (CADDRA): Canadian ADHD Practice Guidelines. 1st ed. Toronto, Ontario: CADDRA; 2006.
23. Zhang S, Faries DE, Vowles M, et al. ADHD Rating Scale IV: psychometric properties from a multinational study as a clinician-administered instrument. Int J Methods Psychiatr Res. 2005;14(4):186-201. (Pubitemid 43013586)
24. Kessler RC, Adler L, Ames M, et al. The prevalence and effects of adult attention deficit/hyperactivity disorder on work performance in a nationally representative sample of workers. J Occup Environ Med. 2005;47(6):565-572. (Pubitemid 40847440)
25. First MB, Spitzer RL, Gibbon M, et al. SCID-I, Clinician Version. Washington, DC: American Psychiatric Press; 1997.
26. Adler LA, Spencer T, Faraone SV, et al. Training raters to assess adult ADHD: reliability of ratings. J Atten Disord. 2005;8(3):121-126. (Pubitemid 40805795)
27. Guy W. ECDEU Assessment Manual for Psychopharmacology-Revised. DHEW Publ No ADM 76-338. Rockville, MD: US Department of Health, Education, and Welfare, Public Health Services, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976.
28. Jenkinson C, Stewart-Brown S, Petersen S, et al. Assessment of the SF-36 version 2 in the United Kingdom. J Epidemiol Community Health. 1999;53 (1):46-50. (Pubitemid 29012351)
29. Kollins SH. A qualitative review of issues arising in the use of psychostimulant medications in patients with ADHD and co-morbid substance use disorders. Curr Med Res Opin. 2008;24(5):1345-1357.
30. Thompson AL, Molina BS, Pelham W Jr, et al. Risky driving in adolescents and young adults with childhood ADHD. J Pediatr Psychol. 2007;32(7):745-759.
31. Biederman J, Faraone SV, Spencer TJ, et al. Functional impairments in adults with self-reports of diagnosed ADHD: a controlled study of 1001 adults in the community. J Clin Psychiatry. 2006;67(4):524-540. (Pubitemid 43764229)
32. Landgraf JM. Monitoring quality of life in adults with ADHD: reliability and validity of a new measure. J Atten Disord. 2007;11(3):351-362.
33. Baron RM, Kenny DA. The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. J Pers Soc Psychol. 1986;51(6):1173-1182.
34. Kraemer HC, Wilson GT, Fairburn CG, et al. Mediators and moderators of treatment effects in randomized clinical trials. Arch Gen Psychiatry. 2002;59(10):877-883.
35. Blalock H. Social Statistics. New York, NY: McGraw Hill; 1972.
36. Weisler RH, Biederman J, Spencer TJ, et al. Mixed amphetamine salts extended-release in the treatment of adult ADHD: a randomized, controlled trial. CNS Spectr. 2006;11(8):625-639. (Pubitemid 44253518)
37. Biederman J, Spencer TJ, Wilens TE, et al. Long-term safety and effectiveness of mixed amphetamine salts extended release in adults with ADHD. CNS Spectr. 2005;10(12, suppl 20):16-25. (Pubitemid 43010494)
38. Newcorn JH, Kratochvil CJ, Allen AJ, et al. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. Am J Psychiatry. 2008;165(6):721-730.
39. Weiss M, Hechtman L. A randomized double-blind trial of paroxetine and/or dextroamphetamine and problem-focused therapy for attention-deficit/ hyperactivity disorder in adults. J Clin Psychiatry. 2006;67(4):611-619. (Pubitemid 43764238)
40. Spencer T, Biederman J, Wilens T, et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005;57(5):456-463. (Pubitemid 40311979)
41. Weiss M, Worling D, Wasdell M. A chart review study of the inattentive and combined types of ADHD. J Atten Disord. 2003;7(1):1-9. (Pubitemid 38030412)
42. Biederman J, Mick E, Faraone SV. Age-dependent decline of symptoms of attention deficit hyperactivity disorder: impact of remission definition and symptom type. Am J Psychiatry. 2000;157(5):816-818. (Pubitemid 30249663)
43. Biederman J, Mick E, Faraone SV, et al. Influence of gender on attention deficit hyperactivity disorder in children referred to a psychiatric clinic. Am J Psychiatry. 2002;159(1):36-42. (Pubitemid 41070724)
44. DuPaul GJ, Schaughency EA, Weyandt LL, et al. Self-report of ADHD symptoms in university students: cross-gender and cross-national prevalence. J Learn Disabil. 2001;34(4):370-379. (Pubitemid 33305623)